OBJECTIVES: To calculate expected mean annual golimumab costs based on observed one-year dosing patterns within a managed care population of psoriatic arthritis (PsA) patients. METHODS: IMS LifeLink™ Health Plan Claims database was utilized to identify patients with: index golimumab claim (4/24/2009-01/06/2010); age ≥18 years at index; ≥1 PsA diagnosis code (696.0); and 12/≥ 12 months pre-/ post-index continuous enrollment. Biologic experience was defined as ≥1 medical/ pharmacy claims for another biologic 12 months prior to the first golimumab prescription. Golimumab utilization was reported as the proportion of patients and prescriptions at the recommended 50 mg dose, and prescription intervals, for the 12 month post-index period. Annual costs were modeled using the golimumab United States wholesale acquisition cost (effective 7/5/2011) of $1,941.65 per 50 mg. RESULTS: 127 PsA patients receiving golimumab (n=914 prescriptions) were identified; 59.8% were female; mean±SD age was 49±10 years. The majority (78.7%) of patients had pre-index biologic experience; 73.0% experienced 1 unique biologic, 24.0% experienced 2 unique biologics, and 3.0% experienced 3+ unique biologics at some time point before golimumab. A 50 mg golimumab dose was dispensed in 95.3% of all PsA patients upon initiation and 96.6% of all prescriptions. The dose at each of the first 12 prescription fills was 50 mg for 95.2%-97.9% of patients. A 50 mg dose was dispensed upon initiation in 94.0% and 100.0% of biologic-experienced and non-biologic-experienced PsA patients, respectively. Overall mean±SD interval between prescriptions was 32±14 days; median was 30 days. Based upon observed prescription intervals, a mean annual acquisition cost of $22,135 would be realized. CONCLUSIONS: The majority of PsA patients receiving golimumab was biologic-experienced and received a 50 mg dose on a monthly basis with no apparent increased dose requirement. Estimated average annual per patient golimumab cost in a managed care PsA population would be $22,135.